A panel of experts discuss recent data results and updates happening within the HER2+ breast cancer treatment landscape.
EP. 1: HER2+ Breast Cancer Treatment Landscape and New Findings Presented at ESMO 2021
Sara A. Hurvitz, MD, briefly describes the treatment landscape for HER2+ breast cancer and the panelists take an in-depth look at the data from the DESTINY-Breast03 trial.
EP. 2: HER2+ Breast Cancer Findings Presented at ESMO 2021: Using T-DXd in Practice
Experts discuss the use of trastuzumab-deruxtecan (T-DXd) in clinical practice.
EP. 3: Clinical Utility of the Data from ESMO 2021 in HER2+ Breast Cancer
The panel analyzes the data from DESTINY-Breast03 and DESTINY-Breast01 and how these data will further impact practice.
EP. 4: A Review of the Data from the HER2CLIMB-04 and TUXEDO-1 Trials
Reshma Mahtani, DO, and Neil Iyengar, MD, discuss the data presented at ESMO 2021 in the TUXEDO-1 and HER2CLIMB-04 trials.
EP. 5: A New ADC and The TULIP Trial
Our panel of experts review the latest data on the antibody drug conjugate, trastuzumab duocarmazine.
EP. 6: Audience Response to Updates from ESMO 2021
Reshma Mahtani, DO, discusses considerations for use of trastuzumab duocarmazine in HER2+ breast cancer.
EP. 7: Patient Case 1: 62-Year-Old Woman With a Palpable Lump in Right Breast
Patient Case 1 is presented to the panel, and Vijayakrishna Gadi, MD, PhD, shares his thoughts on how to approach treatment of this patient.
EP. 8: Patient Case 2: 56-Year-Old Woman Presented With New Right Breast Mass
Patient Case 2 is presented, and Dr Gadi and Dr Mahtani detail how they would proceed with treating this patient.
EP. 9: Managing Toxicities and Special Considerations in the Treatment of HER2+ Breast Cancer
The panelists share their insights on managing toxicities and special considerations in the treatment of HER2+ breast cancer.
EP. 10: Clinical Pearls for HER2+ Breast Cancer Treatment
Experts provide clinical pearls to the audience on treating patients with breast cancer.
EP. 11: Updates in Treating HER2-Positive Breast Cancer
A panel of experts led by Sara Hurvitz, MD, discuss recent data within the HER2-positive breast cancer treatment landscape.
2 Clarke Drive Cranbury, NJ 08512